Treatment with both ruxolitinib and a selective PIM1 inhibitor synergistically reduced the proliferation of an IL-7Rα mutant T-ALL cell line in vitro and leukemic burden in a PDX model of JAK3 mutant T-ALL in vivo [98]. The gene discussed is PIM1; the disease is acute lymphoblastic leukemia.